FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. (NASDAQ: GTCB) (the “Company”) received a notice of non-compliance on July 16, 2008, from the NASDAQ Staff indicating that the Company had not regained compliance with the minimum $1.00 bid price requirement for continued listing on The NASDAQ Global Market, as set forth in NASDAQ Marketplace Rule 4450(a)(5) (the “Minimum Bid Price Rule”). The Company’s common stock is subject to delisting unless the Company requests a hearing before a NASDAQ Listing Qualifications Panel (“Panel”). The Company intends to request a hearing, which will stay any delisting action pending issuance of the Panel’s decision subsequent to the hearing. There can be no assurance that the Panel will grant the Company’s request for continued listing.
